ACT ON BACT | Linksium
Back to portfolio

ACT ON BACT

Available licenses

Original antibiotic compounds

profilePhoto   Christine Melay
Linksium Contact Christine Melay +33 (0)6 21 77 19 90 christine.melay@linksium.fr
160107 ACTONBACT

Benefits

  • New classes of antibacterial agents

Key words

  • Antibiotic Bacterial resistance Gram +

Intellectual Property

  • 3 patents

Laboratory

  • DCM

Institutions

  • CNRS
  • UGA

Linksium Continuum

  • Maturation
  • Commercialization

Results

  • Available licenses

Context

65% of nosocomial bacterial infections are currently caused by six pathogenic species classified under the acronym 'ESKAPE', as they elude the action of most classes of available antibiotics by developing multidrug resistance mechanisms.

Technology

ACT ON BACT is putting forward two classes of synthetic compounds with new structures characterised by original action mechanisms limiting the rapid acquisition of resistance by the bacteria.

Advantages

  • Strong activity regarding the multidrug-resistant Staphylococcus and Enterococcus species
  • Original action mechanisms
  • Efficient and rapid syntheses
  • Low cost

State of progress

Antibacterial activity of the two families was evaluated in vitro.Improved solubility to reduce the plasma protein bindingIdentification of action mechanismsLow spontaneous mutation rates: 10-7 to 10-9 In vivo Studies planned with animal models.

Applications

Pharmaceutical application: applications in systemic treatment (Original structures and modes of action)